실적분석 2026년 8월 12일

Liquidia ($LQDA) Q2 2026 Earnings Analysis — Yutrepia Revenue Slightly Beats Estimates, Mild After-Hours Weakness

Earnings Scorecard

Revenue: Total revenue $171M (product revenue ~$170.4M · services $1.3M, ~+2,520% YoY, vs. $168M estimate) ✅ Beat

EPS (Earnings Per Share): GAAP basic $0.84 · diluted $0.74 (vs. adjusted estimate $0.84; adjusted EPS not disclosed, limiting direct comparison)

Guidance: Not provided

Stock reaction: After-hours -1.99% ($86.3) — as of 08-12 20:42 KST

The Positives

Yutrepia revenue growth: Q2 product revenue of approximately $170.4 million plus services revenue of $1.3 million brought total revenue to $171 million, with product revenue up 31% from the prior quarter

Four consecutive quarters of profitability: Net income $74.7M, adjusted EBITDA $96.3M

Patient and prescription expansion: Surpassed approximately 5,900 prescriptions and 5,000 treated patients since launch

Commercialization of the therapies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease is the central driver of results. Cash and equivalents of $284 million at quarter-end further strengthened the financial position.

The Negatives

Guidance gap: No official forecast provided for next-quarter or full-year revenue and earnings

Sharp cost increase: R&D expenses up 185% YoY; SG&A up 48%

Litigation risk: Ongoing lawsuit with United Therapeutics related to Yutrepia

Injection promotion services revenue declined, and diluted EPS came in below basic EPS, indicating a dilutive share-count impact. In a richly valued range, a modest upside surprise may not be enough to sustain share-price momentum.

What Management Said

CEO Roger Jeffs assessed that Yutrepia has established itself as the inhaled prostacyclin option of choice. Building on its leadership in tolerability and dosing flexibility, the company signaled its next move with the initiation of L606's pivotal trial (LIQRELIANCE).

Market Reaction and Key Points Ahead

The commercialization growth trajectory was confirmed, but the upside versus estimates was modest and guidance was absent, which appears to have triggered profit-taking pressure.

Investors need to confirm that next-quarter Yutrepia revenue growth and the pace of new patient adds continue without deceleration.

Progress in L606 LIQRELIANCE trial enrollment and timeline updates will be the key variable for pipeline value.

The progression of the litigation with United Therapeutics could determine the durability of commercialization.